Stereotactic ablative radiotherapy (SABR) for pelvic nodal oligorecurrence in prostate cancer
Abstract
Background: This study evaluated the clinical outcomes of stereotactic ablative radiotherapy (SABR) in the treatment of oligometastatic pelvic node prostate cancer to delay androgen deprivation therapy (ADT).
Materials and methods: Pelvic lymph node metastases were identified by 11C-choline positron emission tomography (PET)-computed tomography (CT), and patients were not receiving ADT. SABR was administered using linear accelerators with intensity-modulated and image-guided radiotherapy, at a prescribed dose of 35 Gy in 5 fractions over 2 weeks. Response was assessed using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria, and prostate-specific antigen (PSA) levels were monitored post-SABR. Toxicity and quality of life were assessed by the Common Terminology Criteria for Adverse Events Toxicity (CTCAE) v.5.0 and European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaires QLQ-C30/QLQ-PR25, respectively. Kaplan-Meier and T-test were used for statistical analysis.
Results: Between June 2015 and November 2023, 56 patients with 85 lesions were treated at our institution. Median follow-up was 30 months [95% confidence interval (CI): 24–33.6]. Prostatectomy was the radical treatment in 85.7% of patients, and radiotherapy in 14.3%. Response rates were 67.1% for complete response, 27.4% for partial response, and 1.4% for stable disease. In-field progression was observed in only 3 lesions (3.5%). The median time to biochemical relapse post-SABR was 15 months (95% CI: 11.4–18.6). Three-year pelvic nodal and distant progression-free survival were 62.5% and 80%, respectively. There was a significant decrease in PSA levels after SABR compared to pretreatment levels (0.77 vs. 2.16 ng/mL respectively, p = 0.001). No grade ≥ 2 genitourinary or gastrointestinal toxicities. The median global health status score was 83.33 points at both time points analysed.
Conclusion: SABR can delay the ADT and provide excellent local control while preserving quality of life.
Keywords: stereotactic ablative radiotherapyoligorecurrenceprostate canceroligometastasespelvic lymph nodes
References
- Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1): 17–48.
- Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65(4): 965–974.
- Shore ND, Moul JW, Pienta KJ, et al. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 2024; 27(2): 192–201.
- Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011; 8(6): 378–382.
- Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21(1): e18–e28.
- Soldatov A, von Klot CAJ, Walacides D, et al. Patterns of Progression After Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019; 103(1): 95–104.
- Chen X, Chen H, Poon I, et al. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis. Cancer Med. 2021; 10(18): 6189–6198.
- Gundem G, Van Loo P, Kremeyer B, et al. ICGC Prostate UK Group*, ICGC Prostate Group. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015; 520(7547): 353–357.
- Galgano SJ, McDonald AM, West JT, et al. Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer. Cancers (Basel). 2022; 14(14).
- Deek MP, Van der Eecken K, Sutera P, et al. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J Clin Oncol. 2022; 40(29): 3377–3382.
- Pasqualetti F, Trippa F, Aristei C, et al. Stereotactic radiotherapy for oligometastases in the lymph nodes. Rep Pract Oncol Radiother. 2022; 27(1): 46–51.
- Gallizia E, Ferrara E, Beldì D, et al. Stereotactic ablative radiotherapy for oligometastatic prostate cancer. Rep Pract Oncol Radiother. 2022; 27(5): 778–786.
- Palacios-Eito A, Béjar-Luque A, Rodríguez-Liñán M, et al. Oligometastases in prostate cancer: Ablative treatment. World J Clin Oncol. 2019; 10(2): 38–51.
- Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010; 37(8): 4078–4101.
- Glicksman RM, Ramotar M, Metser Ur, et al. Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022; 114(4): 693–704.
- Hölscher T, Baumann M, Kotzerke J, et al. Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. Eur Urol Oncol. 2022; 5(1): 44–51.
- Siva S, Bressel M, Murphy DG, et al. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. Eur Urol. 2018; 74(4): 455–462.
- Phillips R, Shi WY, Deek M, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020; 6(5): 650–659.
- Yan M, Moideen N, Bratti VF, et al. Stereotactic body radiotherapy (SBRT) in metachronous oligometastatic prostate cancer: a systematic review and meta-analysis on the current prospective evidence. Br J Radiol. 2020; 93(1116): 20200496.
- Viani GA, Arruda CV, Hamamura AC, et al. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Recurrence: A Meta-analysis. Am J Clin Oncol. 2020; 43(2): 73–81.
- Muldermans JL, Romak LB, Kwon ED, et al. Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016; 95(2): 696–702.
- Decaestecker K, De Meerleer G, Lambert B, et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol. 2014; 9(5): 135–453.
- Triggiani L, Mazzola R, Magrini SM, et al. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer. 2017; 116(12): 1520–1525.
- Spaas M, Sundahl N, Hulstaert E, et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2018; 36(5): 446–453.
- Ost P, Jereczek-Fossa BA, Van As N, et al. Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences. Clin Oncol (R Coll Radiol). 2016; 28(9): e115–e120.
- Rischke HC, Schultze-Seemann W, Wieser G, et al. Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only. Strahlenther Onkol. 2015; 191(4): 310–320.
- Supiot S, Vaugier L, Pasquier D, et al. OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer. Eur Urol. 2021; 80(4): 405–414.
- Ost P, Siva S, Brabrand S, et al. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. 2024; 7(3): 462–468.
- Conde-Moreno AJ, Lopez F, Hervas A, et al. Phase II Trial of SBRT and Androgen Deprivation for Oligometastases in Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021; 111(S3): S59.
- Deek MP, Taparra K, Dao D, et al. Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021; 109(2): 387–395.
- Sutera P, Song Y, Shetty AC, et al. Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer. Eur Urol. 2023; 84(6): 531–535.
- Tang C, Sherry AD, Haymaker C, et al. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023; 9(6): 825–834.
- Marvaso G, Ciardo D, Corrao G, et al. Radioablation +/- hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159). BMC Cancer. 2019; 19(1): 903.
- Rans K, Charlien B, Filip A, et al. SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival? BMC Cancer. 2022; 22(1): 1294.
- Koontz B, Karrison T, Pisansky T, et al. NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN). J Clin Oncol. 2023; 41(6_suppl): TPS283–TPS283.